Bipolar I Disorder Exacerbation Following COVID-19 Vaccination

A 60-year-old African American female with previously stable bipolar I disorder (BD1) presented after three weeks of depressed mood, anxiety, and decreased need for sleep. Patient Health Questionnaire-9 (PHQ-9) - a widely used tool for diagnosing depression was administered and her score was 5. Her symptoms began within a week of receiving the second dose of the Pfizer-BioNTech COVID-19 vaccine. She was assessed a PHQ-9 score of 0 17 days before vaccination. Her prescription of risperidone 2mg was temporarily increased to 3mg, and her symptoms returned to baseline after two weeks. 


A 40-year-old white male with previously stable BD1 and attention deficit hyperactivity disorder (ADHD) was voluntarily hospitalized due to a mixed episode with psychotic features. His symptoms began after receiving the second dose of the Moderna COVID-19 vaccine and subsequently worsened after he discontinued his medications five days prior to admission. His symptoms stabilized after 10 days of treatment. 

READ MORE


REFERENCE

Guina J, Barlow S, Gutierrez D. Bipolar I Disorder Exacerbation Following COVID-19 Vaccination. Innov Clin Neurosci. 2022 Jul-Sep;19(7-9):9-11. PMID: 36204171; PMCID: PMC9507143.

Comments

Popular posts from this blog

Study linking excess deaths and SARS-CoV2 vaccinations in Scotland

Octuple-COVID-19-vaccinated politician dies from COVID-19 at 75

Breakthrough long COVID in a patient with rheumatoid arthritis